Improved humoral immunogenicity with mRNA-1273 versus BNT162b2 as third vaccine dose among solid organ transplant recipients seronegative after two BNT162b2 doses.
作者信息
Chang Amy, Chiang Teresa Py, Kim Jake D, Mitchell Jonathan, Alejo Jennifer L, Jefferis Alexa A, Avery Robin K, Tobian Aaron A R, Levan Macey L, Warren Daniel S, Garonzik-Wang Jacqueline M, Massie Allan B, Segev Dorry L, Werbel William A
机构信息
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
出版信息
Clin Transplant. 2022 Aug;36(8):e14738. doi: 10.1111/ctr.14738. Epub 2022 Jun 14.
Abstract
摘要
相似文献
1
Improved humoral immunogenicity with mRNA-1273 versus BNT162b2 as third vaccine dose among solid organ transplant recipients seronegative after two BNT162b2 doses.在接受两剂BNT162b2后血清学阴性的实体器官移植受者中，与BNT162b2相比，mRNA-1273作为第三剂疫苗可提高体液免疫原性。
Clin Transplant. 2022 Aug;36(8):e14738. doi: 10.1111/ctr.14738. Epub 2022 Jun 14.
2
Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination.异源 Ad.26.COV2.S 与同源 BNT162b2/mRNA-1273 作为两剂 mRNA 疫苗接种后血清阴性的实体器官移植受者的第三剂。
Am J Transplant. 2022 Sep;22(9):2254-2260. doi: 10.1111/ajt.17061. Epub 2022 May 3.
3
Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis.两种 mRNA 疫苗（BNT162b2 和 mRNA-1273）在实体器官移植受者中进行两剂基础免疫后的血清转化率：系统评价和荟萃分析。
Nephrol Dial Transplant. 2022 Jul 26;37(8):1566-1575. doi: 10.1093/ndt/gfac174.
4
Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients.肾移植受者中mRNA-1273和BNT162b2新冠病毒mRNA疫苗免疫原性的比较
Transpl Int. 2022 Jan 4;35:10026. doi: 10.3389/ti.2021.10026. eCollection 2021.
5
Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19-BNT162b2 mRNA Vaccination.腺病毒载体 ChAdOx1 nCoV-19（阿斯利康-牛津）-BNT162b2 mRNA 疫苗异源接种对肺移植受者免疫原性的影响。
Viruses. 2022 Jul 2;14(7):1470. doi: 10.3390/v14071470.
6
mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?mRNA-1273疫苗（莫德纳）：对于肾移植受者和透析患者而言，它比BNT162b2（辉瑞）疫苗是更好的选择吗？
Nephrol Dial Transplant. 2022 Mar 25;37(4):799-803. doi: 10.1093/ndt/gfab352.
7
Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.实体器官移植受者中灭活 SARS-CoV-2 疫苗和 BNT162b2 mRNA 疫苗的抗体反应差异。
Exp Clin Transplant. 2021 Dec;19(12):1334-1340. doi: 10.6002/ect.2021.0402.
8
Seroconversions After Withdrawal From Mycophenolate Mofetil in Solid Organ Transplant Recipients Without a Third Dose of BNT162b2 mRNA Coronavirus Disease 2019 Vaccine: A Case Series.实体器官移植受者停用吗替麦考酚酯后在未接种第三剂BNT162b2 mRNA新型冠状病毒肺炎疫苗情况下的血清学转换：病例系列
Transplantation. 2022 Apr 1;106(4):e238-e239. doi: 10.1097/TP.0000000000004043.
9
Waning humoral immune response to the BNT162b2 vaccine in heart transplant recipients over 6 months.心脏移植受者在6个月以上对BNT162b2疫苗的体液免疫反应减弱。
Am J Transplant. 2022 Jul;22(7):1931-1932. doi: 10.1111/ajt.16998. Epub 2022 Mar 1.
10
Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）BNT162b2疫苗在实体器官移植受者中的免疫原性。
Am J Transplant. 2021 Aug;21(8):2913-2915. doi: 10.1111/ajt.16607. Epub 2021 May 7.
引用本文的文献
1
Effectiveness of heterologous and homologous COVID-19 vaccination among immunocompromised individuals: a systematic literature review and meta-analysis.免疫功能低下个体中异源和同源COVID-19疫苗接种的有效性：一项系统文献综述和荟萃分析。
Antimicrob Steward Healthc Epidemiol. 2024 Sep 26;4(1):e152. doi: 10.1017/ash.2024.369. eCollection 2024.
2
Susceptibility to SARS-CoV-2 Infection and Immune Responses to COVID-19 Vaccination Among Recipients of Solid Organ Transplants.实体器官移植受者对 SARS-CoV-2 感染的易感性和对 COVID-19 疫苗接种的免疫反应。
J Infect Dis. 2023 Aug 4;228(Suppl 1):S34-S45. doi: 10.1093/infdis/jiad152.
Zotero 插件